ACLY

Across TCGA pan-cancer cohorts, ACLY RNA is linked to patient survival in 29 of 34 cancer types, making it the most broadly survival-associated ACLY data layer compared with 8 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ACLY RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACLY expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

MESO, KIRC, and ACC are the cancer types where ACLY RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.277	0.492	<.001	102	view →
KIRC	OS	Median	All	0.723	0.540	<.001	94	view →
ACC	DFS	Median	All	0.227	0.697	<.001	84	view →
UVM	DFS	Tertile	All	0.290	0.741	.001	68	view →
LIHC	DFS	Median	All	0.460	0.622	<.001	66	view →
CESC	DFS	Tertile	All	0.621	0.855	<.001	60	view →
BLCA	DFS	Quartile	All	0.224	0.595	<.001	55	view →
KICH	OS	Median	II,III,IV	0.625	0.959	.003	47	view →
OV	OS	Quartile	III,IV	0.751	0.855	.004	32	view →
SARC	DFS	Quartile	All	0.156	0.535	<.001	28	view →
LUSC	DFS	Tertile	III,IV	0.277	0.935	.002	25	view →
KIRP	DFS	Median	All	0.873	0.943	.008	24	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 29 lineages.

ACLY–MESO (OS)

Open the MESO breakdown →